I

Immunic Therapeutics

Clinical-stage biopharma developing oral autoimmune therapies

Director – Scientific Communications

Technical WritingConfirmed live in the last 24 hours
Full-timeRemote in USA$230k - $255k /yrRemote

About the Job

Requirements

  • An advanced scientific or clinical degree, such as a PhD, PharmD, MD, or equivalent, is required.
  • A strong scientific writing and communication background is required.
  • At least 8 years of relevant experience in scientific communications, publications, Medical Affairs, medical communications, or related biopharma functions is required.
  • Demonstrated experience developing and executing publication plans, scientific platforms, congress plans, manuscripts, abstracts, posters, presentations, and other evidence dissemination deliverables is required.
  • Strong working knowledge of Good Publication Practice, ICMJE authorship criteria, publication ethics, medical/legal/regulatory review processes, and industry expectations for transparency and scientific integrity is required.
  • Proven ability to select, manage, and lead external agencies, medical writers, publication partners, and other vendors to deliver high-quality work on time and within budget is required.
  • Ability to lead through influence, implement strategic direction, oversee complex cross-functional workstreams, and build scalable capabilities in an evolving organization is required.
  • Ability to translate complex science into clear, accurate, and audience-appropriate content for internal and external stakeholders is required.
  • Strong prioritization, project management, and problem-solving skills are required, with comfort operating in a smaller, pre-commercial biotech environment where processes are being built and priorities may evolve.

Responsibilities

  • Lead and oversee implementation of integrated scientific communications plans for vidofludimus calcium and Immunic’s broader pipeline, including publications, congress materials, field medical content, and related Medical Affairs resources.
  • Translate Medical Affairs priorities and evolving evidence into integrated workplans, prioritized deliverables, timelines, and execution roadmaps.
  • Operationalize and maintain the scientific platform, lexicon, dissemination framework, and core narrative to support consistent Medical Affairs communication.
  • Manage publication planning operations, including publication plans, steering committee activities, author engagement, abstracts, posters, and manuscripts.
  • Ensure publications and scientific communications follow Good Publication Practice, ICMJE authorship criteria, applicable industry standards, and internal review processes.
  • Lead Medical Affairs congress and field content planning, including scientific messaging, congress debriefs, modular resources, training content, FAQs, evidence summaries, and related tools.
  • Partner with Field Medical leadership to identify content needs, incorporate field insights, and keep resources timely, relevant, and aligned with launch-readiness priorities.
  • Manage literature surveillance to monitor emerging data, congress outputs, publications, treatment landscape developments, and other information relevant to Medical Affairs priorities.
  • Synthesize competitive intelligence and external scientific developments into actionable insights for narrative refinement, content planning, congress readiness, and cross-functional decision-making.
  • Recommend content updates, communication priorities, and risk-mitigation actions based on emerging evidence, field insights, and competitive intelligence.
  • Partner with Medical Affairs Operations to establish scalable content standards, templates, review processes, and operating models, including lifecycle practices for version control, periodic review, updates, archival, and retirement.
  • Partner with Medical Review, Medical Information, HEOR, Clinical Development, Market Access, Commercial, Legal, Compliance, Regulatory, and Medical Affairs Operations to ensure scientific communications are aligned, accurate, non-promotional, scalable, and fit for purpose.
  • Select, onboard, manage, and hold external medical communications, publications, and medical writing agencies accountable for quality, timelines, budgets, and contractual deliverables.
  • Provide operational leadership to external partners and cross-functional teams, with accountability for execution quality, prioritization, metrics, and communication of impact.

Desired Qualifications

  • Launch or late-stage development experience is strongly preferred.
  • Experience developing or overseeing field medical content, scientific exchange materials, training content, or related Medical Affairs tools is preferred.
  • Experience in multiple sclerosis, neuroimmunology, neurology, immunology, or another chronic autoimmune or inflammatory disease area is strongly preferred.
  • Experience building scalable scientific communications infrastructure is preferred.
  • Experience with literature surveillance, competitive intelligence monitoring, and synthesis of external scientific developments into actionable Medical Affairs insights is preferred.
  • Experience implementing publication management systems, content management tools, or scalable Medical Affairs operating processes is preferred.

About the Company

Immunic Therapeutics

Clinical-stage biopharma developing oral autoimmune therapies

Immunic Therapeutics develops oral therapies for chronic inflammatory and autoimmune diseases and is in clinical-stage development. Its lead candidate, vidofludimus calcium (IMU-838), is an oral small molecule that activates the Nurr1 receptor to protect nerve cells and inhibits DHODH to calm overactive immune responses; its pipeline also includes IMU-856, a SIRT6 modulator aimed at restoring intestinal barrier function, with IMU-381 in preclinical GI programs. The company emphasizes oral, small-molecule drugs with dual actions and pursues partnerships or licensing for commercialization rather than relying on near-term product revenue. Its goal is to advance its drug candidates through clinical trials toward commercialization, potentially via collaborations with larger pharma companies.

Company size
51-200
Company stage
IPO
Headquarters
New York City, New York
Founded
2016

Recently Posted Jobs

Explore more opportunities at Immunic Therapeutics

See more jobs